Vinge advises Bridgepoint in its agreement to acquire a significant controlling stake in Safe Life, a global leader in the distribution of automated external defibrillators (AEDs), in a transaction that values the company at c. €500 million.

Headquartered in Stockholm, Safe Life operates across North America and Europe and is a market leader in a highly fragmented and fast-growing sector. The company equips communities and workplaces with lifesaving AEDs supported by ongoing services, including CPR training, maintenance and replacement parts such as pads and batteries to enable a fast and effective response in an emergency.

Bridgepoint will partner with Safe Life’s founders and existing institutional investors including Byggmästaren, Bonnier Capital and Swedbank Robur, all of whom are materially reinvesting alongside Bridgepoint.

The transaction is subject to customary regulatory approvals.

Vinge’s team consisted mainly of Daniel Rosvall, Samra Tesser, Johanna Hamrefält, Sara Hammond and Oliwer Vidarsson (M&A), Albert Wållgren, Josefine Lanker, Calle Tengwall Pagels and Gabriel Chabo (Banking and Finance), Mario Saad, Filippa Eriksson and Carla Håkansson (Commercial Agreements, IT and GDPR), Christoffer Nordin (Regulatory Permits), Simon Söderholm and Viktor Lundberg (Employment), Ian Jonson (IP), Hanna Kövamees and Wilma Hellman (Real Estate and Environment), Sebastian Örndahl, Fredrik Hellström and Hilda Ivarsson (FDI), Julia Ulander Kull (Transaction Support Coordinator).

Related

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025

Vinge advises Advania in connection with the acquisition of atNorth HPC AB

Vinge has advised Advania, one of the leading IT companies in the Nordic region, in connection with the acquisition of atNorth HPC AB. The acquisition strengthens Advania's presence within high-performance computing (HPC).
October 03, 2025